Examination of effect of Relaxin (RLX) treatment on young (9-month) and aged (24-month) rats to test the hypothesis that RLX acts at a genomic level to reverse maladaptive remodeling in aging and heart failure. Treatment was 0.4 mg/kg/day RLX for 2-weeks delivered by subcutaneous osmotic mini-pumps or with sodium acetate (controls). There are twenty-one NCBI GEO records, 4 female and 3 male each...